Faces are so important to social communication that we’ve evolved specialized brain cells just to recognize them, a new study ...

Facial expression control starts in a very old part of the nervous system. In the brain stem sits the facial nucleus, which ...

Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

Decades before Alzheimer’s disease symptoms appear, neurons become hyperactive, and the reason could be that astrocytes fail to keep them in check. In a bioRxiv preprint uploaded on April 26, ...

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...

Can drug delivery technology equip Cingulate to win market share from Johnson & Johnson, Novartis and Takeda? That is the question facing investors as they weigh up whether to back Cingulate’s pitch ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate Inc. placed its CEO on ...

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...